Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Panacea Biotec has informed that: (i) the meeting of the Board of Directors of the company is scheduled to be held on Friday, February 14, 2025 at New Delhi, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31, 2024; (ii) pursuant to Regulation 46(2) of the SEBI LODR Regulations, notice of the said meeting is also being uploaded on the website of the Company; and (iii) with reference to its earlier announcement dated December 26, 2024 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct for Prevention of Insider Trading framed in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the trading window of the Company shall remain closed for all Designated Persons of the Company till February 16, 2025.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.30 |
| Dr. Reddys Lab | 1234.00 |
| Cipla | 1231.50 |
| Zydus Lifesciences | 937.50 |
| Lupin | 2329.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: